Total Payments
$483,574
2024 Payments
$3,335
Companies
23
Transactions
407
Medicare Patients
1,551
Medicare Billing
$66,798
Payment Breakdown by Category
Other$214,604 (44.4%)
Consulting$185,573 (38.4%)
Travel$42,639 (8.8%)
Research$32,910 (6.8%)
Food & Beverage$7,841 (1.6%)
Education$6.96 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $203,704 | 83 | 42.1% |
| Consulting Fee | $185,573 | 72 | 38.4% |
| Travel and Lodging | $42,639 | 102 | 8.8% |
| Unspecified | $32,910 | 15 | 6.8% |
| Honoraria | $10,900 | 3 | 2.3% |
| Food and Beverage | $7,841 | 131 | 1.6% |
| Education | $6.96 | 1 | 0.0% |
Payments by Type
General
$450,664
392 transactions
Research
$32,910
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AbbVie Inc. | $272,545 | 237 | $0 (2023) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $67,221 | 38 | $0 (2023) |
| UCB SA | $31,977 | 22 | $0 (2024) |
| UCB, Inc. | $27,586 | 19 | $0 (2024) |
| Incyte Corporation | $23,684 | 31 | $0 (2023) |
| Sun Pharmaceutical Industries Inc. | $12,444 | 16 | $0 (2020) |
| Allergan Inc. | $6,453 | 6 | $0 (2017) |
| Insmed, Inc. | $6,322 | 4 | $0 (2022) |
| Janssen Scientific Affairs, LLC | $6,128 | 2 | $0 (2022) |
| Novartis Pharma AG | $6,050 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,335 | 3 | UCB SA ($2,745) |
| 2023 | $87,156 | 50 | UCB SA ($28,103) |
| 2022 | $97,844 | 79 | Novartis Pharmaceuticals Corporation ($42,166) |
| 2021 | $87,617 | 75 | AbbVie Inc. ($71,594) |
| 2020 | $84,906 | 72 | AbbVie Inc. ($75,817) |
| 2019 | $69,897 | 71 | AbbVie, Inc. ($52,365) |
| 2018 | $23,070 | 26 | AbbVie, Inc. ($18,009) |
| 2017 | $29,749 | 31 | AbbVie, Inc. ($14,885) |
All Payment Transactions
407 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/22/2024 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 02/27/2024 | UCB, Inc. | — | Consulting Fee | Cash or cash equivalent | $590.00 | General |
| 02/09/2024 | UCB SA | — | Food and Beverage | In-kind items and services | $45.25 | General |
| 12/19/2023 | Novartis Pharma AG | COSENTYX (Biological) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: DERMATOLOGY | ||||||
| 11/28/2023 | UCB, Inc. | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $2,905.00 | General |
| Category: Immunology | ||||||
| 10/24/2023 | UCB, Inc. | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $1,770.00 | General |
| Category: Immunology | ||||||
| 10/19/2023 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $47.20 | General |
| Category: Immunology | ||||||
| 10/14/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 10/14/2023 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 10/13/2023 | Incyte Corporation | OPZELURA (Drug) | Consulting Fee | Cash or cash equivalent | $2,450.00 | General |
| Category: Dermatology | ||||||
| 10/13/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $49.30 | General |
| Category: Dermatology | ||||||
| 10/13/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $23.15 | General |
| Category: Dermatology | ||||||
| 09/23/2023 | PFIZER INC. | CIBINQO (Drug) | Food and Beverage | In-kind items and services | $36.89 | General |
| Category: Inflammation & Immunology | ||||||
| 09/23/2023 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $25.44 | General |
| Category: Immunology | ||||||
| 09/22/2023 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $6,325.00 | General |
| 09/22/2023 | UCB, Inc. | — | — | In-kind items and services | $2,300.00 | Research |
| Study: Burden of hidradenitis suppurativa: A systematic literature review of patient reported outcomes | ||||||
| 09/21/2023 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $6,325.00 | General |
| 09/12/2023 | AbbVie Inc. | — | Travel and Lodging | In-kind items and services | $506.52 | General |
| 09/12/2023 | AbbVie Inc. | — | Travel and Lodging | In-kind items and services | $88.40 | General |
| 09/12/2023 | AbbVie Inc. | — | Travel and Lodging | In-kind items and services | $83.88 | General |
| 09/12/2023 | AbbVie Inc. | — | Food and Beverage | In-kind items and services | $29.80 | General |
| 09/12/2023 | AbbVie Inc. | — | Food and Beverage | In-kind items and services | $13.22 | General |
| 09/11/2023 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $2,490.00 | General |
| 09/11/2023 | AbbVie Inc. | — | Travel and Lodging | In-kind items and services | $186.45 | General |
| 06/29/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $19,520 | 4 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH COSENTYX RESEARCH | Novartis Pharmaceuticals Corporation | $2,490 | 1 |
| Burden of hidradenitis suppurativa: A systematic literature review of patient reported outcomes | UCB, Inc. | $2,300 | 1 |
| Electronic Patient-Reported Outcomes in Hidradenitis Suppurativa: Content Validity and Usability of the Electronic Hidradenitis Suppurativa Symptom Da | UCB, Inc. | $2,300 | 1 |
| Validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials | UCB, Inc. | $2,300 | 1 |
| A systematic literature review of health-related quality of life and other patient reported outcomes across key subgroups in hidradenitis suppurativa | UCB, Inc. | $820.00 | 2 |
| Acceptability and usability of the electronic hidradenitis suppurativa quality of life questionnaire | UCB, Inc. | $820.00 | 1 |
| Burden of hidradenitis suppurativa: a systematic literature review of patient reported outcomes | UCB, Inc. | $820.00 | 1 |
| Content validity, acceptability and usability of the electronic hidradenitis suppurativa symptom daily diary and the electronic hidradenitis suppurati | UCB, Inc. | $820.00 | 1 |
| A PHASE 2 MULTICENTER, INVESTIGATOR-BLIND, SUBJECT-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF BIMEKIZUMAB IN SUB | UCB, Inc. | $420.00 | 1 |
| QUALITATIVE STUDY OF PATIENTS WITH HIDRADENITIS SUPPURATIVA COGNITIVE DEBRIEFING INTERVIEWS FOR PATIENT REPORTED OUTCOMES INSTRUMENT DEVELOPMENT | NOVARTIS PHARMACEUTICALS CORPORATION | $300.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 386 | 489 | $83,850 | $15,077 |
| 2022 | 8 | 380 | 492 | $70,419 | $15,476 |
| 2021 | 12 | 460 | 567 | $101,132 | $22,429 |
| 2020 | 10 | 325 | 381 | $75,940 | $13,816 |
Total Patients
1,551
Total Services
1,929
Medicare Billing
$66,798
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 116 | 129 | $31,605 | $5,684 | 18.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Facility | 2023 | 47 | 52 | $10,348 | $1,830 | 17.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 19 | 21 | $7,560 | $1,599 | 21.2% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Facility | 2023 | 17 | 21 | $8,379 | $1,586 | 18.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 57 | 60 | $7,980 | $1,437 | 18.0% |
| 11102 | Biopsy of related skin growth, first growth | Facility | 2023 | 50 | 58 | $8,004 | $1,311 | 16.4% |
| 17110 | Destruction of skin growth, 1-14 growths | Facility | 2023 | 29 | 30 | $7,230 | $1,093 | 15.1% |
| 11103 | Biopsy of related skin growth, each additional growth | Facility | 2023 | 19 | 25 | $2,000 | $420.91 | 21.0% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Facility | 2023 | 32 | 93 | $744.00 | $116.09 | 15.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 109 | 127 | $24,793 | $6,021 | 24.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 76 | 82 | $7,656 | $2,083 | 27.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Facility | 2022 | 46 | 51 | $10,293 | $1,834 | 17.8% |
| 11102 | Biopsy of related skin growth, first growth | Facility | 2022 | 57 | 68 | $10,097 | $1,645 | 16.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 17 | 19 | $5,179 | $1,396 | 27.0% |
| 17110 | Destruction of skin growth, 1-14 growths | Facility | 2022 | 24 | 26 | $6,734 | $1,331 | 19.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 13 | $3,076 | $682.38 | 22.2% |
| 11103 | Biopsy of related skin growth, each additional growth | Facility | 2022 | 11 | 20 | $1,743 | $344.79 | 19.8% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Facility | 2022 | 27 | 86 | $848.00 | $139.69 | 16.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 107 | 125 | $17,000 | $6,129 | 36.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 42 | 47 | $9,823 | $3,332 | 33.9% |
| 12032 | Repair of wound (2.6 to 7.5 centimeters) of the scalp, underarms, trunk, arms, and/or legs | Facility | 2021 | 17 | 17 | $12,971 | $2,362 | 18.2% |
| 17000 | Destruction of skin growth | Facility | 2021 | 61 | 67 | $13,735 | $2,304 | 16.8% |
| 17262 | Destruction of malignant growth (1.1 to 2.0 centimeters) of trunk, arms, or legs | Facility | 2021 | 21 | 21 | $9,597 | $1,612 | 16.8% |
| 11602 | Removal of malignant growth (1.1 to 2.0 centimeters) of the trunk, arms, or legs | Facility | 2021 | 17 | 18 | $11,682 | $1,536 | 13.2% |
| 17110 | Destruction of up to 14 skin growths | Facility | 2021 | 29 | 31 | $8,277 | $1,500 | 18.1% |
About Dr. Joslyn Sciacca Kirby, MD
Dr. Joslyn Sciacca Kirby, MD is a Dermatology healthcare provider based in Hershey, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1821158767.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joslyn Sciacca Kirby, MD has received a total of $483,574 in payments from pharmaceutical and medical device companies, with $3,335 received in 2024. These payments were reported across 407 transactions from 23 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($203,704).
As a Medicare-enrolled provider, Sciacca Kirby has provided services to 1,551 Medicare beneficiaries, totaling 1,929 services with total Medicare billing of $66,798. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Hershey, PA
- Active Since 12/11/2006
- Last Updated 08/05/2009
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1821158767
Products in Payments
- HUMIRA (Biological) $165,175
- Humira (Biological) $45,248
- COSENTYX (Biological) $35,732
- COSENTYX (Drug) $19,147
- ABSORICA (Drug) $12,387
- TREMFYA (Drug) $6,128
- TAVNEOS (Drug) $6,000
- Bimzelx (Biological) $4,883
- ACZONE (Drug) $4,623
- KX2-391 Ointment (Drug) $2,608
- OPZELURA (Drug) $2,563
- SKYRIZI (Biological) $1,403
- DUPIXENT (Biological) $159.78
- DERMABOND (Device) $123.07
- Skyrizi (Biological) $98.69
- ABSORICA LD (Drug) $57.27
- Sotyktu (Drug) $53.50
- Cimzia (Drug) $43.30
- CIBINQO (Drug) $36.89
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Hershey
Andrea Zaenglein, Md, MD
Dermatology — Payments: $100,541
Dermatology $100,541
Elizabeth Billingsley, Md, MD
Dermatology — Payments: $19,726
Dermatology $19,726
Diane Thiboutot, Md, MD
Dermatology — Payments: $17,793
Dermatology $17,793
Charlene Lam, Md, MD
Dermatology — Payments: $10,488
Dermatology $10,488
Jeffrey Miller, Md, MD
Dermatology — Payments: $1,523
Dermatology $1,523
Natasha Marvi, M.d, M.D
Dermatology — Payments: $1,405
Dermatology $1,405